{"nctId":"NCT03338816","briefTitle":"ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)","startDateStruct":{"date":"2017-11-16","type":"ACTUAL"},"conditions":["Acute Hepatic Porphyria","Acute Intermittent Porphyria","Porphyria, Acute Intermittent","Acute Porphyria","Hereditary Coproporphyria (HCP)","Variegate Porphyria (VP)","ALA Dehydratase Deficient Porphyria (ADP)"],"count":94,"armGroups":[{"label":"Givosiran/Givosiran","type":"EXPERIMENTAL","interventionNames":["Drug: Givosiran","Drug: Placebo"]},{"label":"Placebo/Givosiran","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Givosiran","Drug: Placebo"]}],"interventions":[{"name":"Givosiran","otherNames":["ALN-AS1","GIVLAARI"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* â‰¥ 12 years of age\n* Diagnosed with Acute Hepatic Porphyria (Acute Intermittent Porphyria, Hereditary Corproporhyria, Variegate Porphyria, aminolevulinic acid (ALA) dehydratase deficient porphyria)\n* Elevated urinary or plasma porphobilinogen (PBG) or ALA values within the past year,\n* Have active disease, with at least 2 documented porphyria attacks within the last 6 months\n* Willing to discontinue or not initiate the use of prophylactic hemin throughout the study.\n* Women of child bearing potential must have a negative serum pregnancy test, not be nursing, and use acceptable contraception\n\nExclusion Criteria:\n\n* Clinically significant abnormal laboratory results\n* Anticipated liver transplantation\n* History of multiple drug allergies or intolerance to subcutaneous injections\n* Active HIV, hepatitis C virus, or hepatitis B virus infection(s)\n* History of recurrent pancreatitis","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Annualized Rate of Porphyria Attacks in Participants With Acute Intermittent Porphyria (AIP)","description":"Porphyria attacks were defined as meeting all of the following criteria: an acute episode of neurovisceral pain in the abdomen, back, chest, extremities and/or limbs, no other medically determined cause, and required treatment with intravenous (IV) dextrose or hemin, carbohydrates, or analgesics, or other medications such as antiemetics at a dose or frequency beyond the participant's usual daily porphyria management. The annualized rate of porphyria attacks is a composite endpoint which included porphyria attacks requiring hospitalization, urgent healthcare visit, or IV hemin administration at home.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.52","spread":null},{"groupId":"OG001","value":"3.22","spread":null}]}]}]},{"type":"SECONDARY","title":"The Pharmacodynamic (PD) Effect of Givosiran on Urine Levels of Delta-aminolevulinic Acid (ALA) in Participants With AIP","description":"The PD effect of givosiran was evaluated by spot urine ALA levels normalized to spot urine creatinine levels.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.965","spread":"1.475"},{"groupId":"OG001","value":"1.756","spread":"1.413"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.150","spread":"2.534"},{"groupId":"OG001","value":"4.013","spread":"2.352"}]}]}]},{"type":"SECONDARY","title":"The PD Effect of Givosiran on Urine Levels of Porphobilinogen (PBG) in Participants With AIP","description":"The PD effect of givosiran was evaluated by spot urine PBG levels normalized to spot urine creatinine levels.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.110","spread":"4.959"},{"groupId":"OG001","value":"12.906","spread":"4.642"}]}]}]},{"type":"SECONDARY","title":"Annualized Rate of Hemin Administration in Participants With AIP","description":"Annualized rate of hemin doses was evaluated as annualized days of hemin use.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.71","spread":null},{"groupId":"OG001","value":"6.77","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Rate of Porphyria Attacks in Participants With AHP","description":"Porphyria attacks were defined as meeting all of the following criteria: an acute episode of neurovisceral pain in the abdomen, back, chest, extremities and/or limbs, no other medically determined cause, and required treatment with intravenous (IV) dextrose or hemin, carbohydrates, or analgesics, or other medications such as antiemetics at a dose or frequency beyond the participant's usual daily porphyria management. The annualized rate of porphyria attacks is a composite endpoint which included porphyria attacks requiring hospitalization, urgent healthcare visit, or IV hemin administration at home.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.26","spread":null},{"groupId":"OG001","value":"3.35","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve (AUC) of the Change From Baseline in Weekly Mean Score of Daily Worst Pain as Measured by the Brief Pain Inventory-Short Form (BPI-SF) Numeric Rating Scale (NRS) in Participants With AIP","description":"Participants rated worst daily pain score in an eDiary using the 11-point BPI-SF NRS, in which 0=no pain and 10=worst pain. Daily eDiary entries were averaged into a weekly (i.e. 7 day) score. The change from baseline in weekly mean scores is defined as the post baseline weekly mean score minus the baseline score. Lower scores indicate an improvement. The 6-month AUC was calculated based on change from baseline in weekly mean scores.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.286","spread":null},{"groupId":"OG001","value":"-11.514","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Change From Baseline in Weekly Mean Score of Daily Worst Pain as Measured by the Brief Pain Inventory-Short Form (BPI-SF) Numeric Rating Scale (NRS) in Participants With AIP","description":"Participants rated worst daily pain score in an eDiary using the 11-point BPI-SF NRS, in which 0=no pain and 10=worst pain. Daily eDiary entries were averaged into a weekly (i.e. 7 day) score. The change from baseline in weekly mean scores is defined as the postbaseline weekly mean score minus the baseline score. Lower scores indicate an improvement.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.245","spread":null},{"groupId":"OG001","value":"-0.506","spread":null}]}]}]},{"type":"SECONDARY","title":"AUC of the Change From Baseline in Weekly Mean Score of Daily Worst Fatigue Score as Measured by the Brief Fatigue Inventory-Short Form (BFI-SF) NRS in Participants With AIP","description":"Participants rated daily worst fatigue score in an eDiary using the 11-point BFI-SF NRS, in which 0=no fatigue and 10=worst fatigue. Daily eDiary entries were averaged into a weekly (i.e. 7 day) score. The change from baseline in weekly mean scores is defined as the post baseline weekly mean score minus the baseline score. Lower scores indicate an improvement. The 6-month AUC was calculated based on change from baseline in weekly mean scores.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.208","spread":"4.689"},{"groupId":"OG001","value":"-11.148","spread":"4.501"}]}]}]},{"type":"SECONDARY","title":"Average Change From Baseline in Weekly Mean Score of Daily Worst Fatigue Score as Measured by the Brief Fatigue Inventory-Short Form (BFI-SF) NRS in Participants With AIP","description":"Participants rated daily worst fatigue score in an eDiary using the 11-point BFI-SF NRS, in which 0=no fatigue and 10=worst fatigue. Daily eDiary entries were averaged into a weekly (i.e. 7 day) score. The change from baseline in weekly mean scores is defined as the postbaseline weekly mean score minus the baseline score. Lower scores indicate an improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.182","spread":"0.209"},{"groupId":"OG001","value":"-0.502","spread":"0.200"}]}]}]},{"type":"SECONDARY","title":"AUC of the Change From Baseline in Weekly Mean Score Daily Worst Nausea Score as Measured by NRS in Participants With AIP","description":"Participants rated worst daily nausea score in an eDiary using an 11-point NRS, in which 0=no nausea and 10=worst nausea. Daily eDiary entries were averaged into a weekly (i.e. 7 day) score. The change from baseline in weekly mean scores is defined as the postbaseline weekly mean score minus the baseline score. Lower scores indicate an improvement. The 6-month AUC was calculated based on change from baseline in weekly mean scores.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.011","spread":"3.453"},{"groupId":"OG001","value":"1.481","spread":"3.310"}]}]}]},{"type":"SECONDARY","title":"Average Change From Baseline in Weekly Mean Score Daily Worst Nausea Score as Measured by NRS in Participants With AIP","description":"Participants rated worst daily nausea score in an eDiary using an 11-point NRS, in which 0=no nausea and 10=worst nausea. Daily eDiary entries were averaged into a weekly (i.e. 7 day) score. The change from baseline in weekly mean scores is defined as the postbaseline weekly mean score minus the baseline score. Lower scores indicate an improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.181","spread":"0.154"},{"groupId":"OG001","value":"0.067","spread":"0.147"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Physical Component Summary (PCS) of the 12-Item Short Form Survey (SF-12) in Participants With AIP","description":"The SF-12 is a survey designed for use in patients with multiple chronic conditions. This 12-item scale can be used to assess the physical and mental health of respondents. 10 of the 12 questions are answered on a 5 point likert scale and 2 are answered on a 3 point likert scale. The questions are then scored and weighted into 2 subscales, physical health and mental health. Respondents can have a score that ranges from 0-100 with 100 being the best score and indicating high physical or mental health. A 3 point change in SF-12 score reflects a meaningful difference. A higher score indicates improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.431","spread":"1.220"},{"groupId":"OG001","value":"5.369","spread":"1.169"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":46},"commonTop":["Nausea","Injection site reaction","Fatigue","Nasopharyngitis","Headache"]}}}